Beyond registration--measuring the public-health potential of new treatments for malaria in Africa. od Lang, T, Hughes, D, Kanyok, T, Kengeya-Kayondo, J, Marsh, V, Haaland, A, Pirmohamed, M, Winstanley, P

Pilot study of Curcuma extract in patients: Safety and biological activity od Sharma, R, McLelland, H, Ireson, C, Jones, D, Hill, K, Euden, SA, Williams, M, Pirmohamed, M, Plummer, S, Manson, M, Gescher, A, Steward, W

A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis. od Foulkes, AC, Watson, DS, Carr, DF, Kenny, JG, Slidel, T, Parslew, R, Pirmohamed, M, PSORT Consortium, Anders, S, Reynolds, NJ, Griffiths, CEM, Warren, RB, Barnes, MR

Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease od Zain, Shamsul Mohd, Mohamed, Zahurin, Pirmohamed, M., Tan, H.L., Alshawsh, Mohammed Abdullah, Mahadeva, Sanjiv, Chan, Wah Kheong, Mustapha, N.R.N., Mohamed, Rosmawati

Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? od Cheung, VTF, Gupta, T, Olsson-Brown, A, Subramanian, S, Sasson, SC, Heseltine, J, Fryer, E, Collantes, E, Sacco, JJ, Pirmohamed, M, Simmons, A, Klenerman, P, Tuthill, M, Protheroe, AS, Chitnis, M, Fairfax, BP, Payne, MJ, Middleton, MR, Brain, O

Phenotype standardization for statin-induced myotoxicity. od Alfirevic, A, Neely, D, Armitage, J, Chinoy, H, Cooper, R, Laaksonen, R, Carr, D, Bloch, K, Fahy, J, Hanson, A, Yue, Q, Wadelius, M, Maitland-van Der Zee, A, Voora, D, Psaty, B, Palmer, C, Pirmohamed, M

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? od Laverty, H, Benson, C, Cartwright, E, Cross, M, Garland, C, Hammond, T, Holloway, C, McMahon, N, Milligan, J, Park, B, Pirmohamed, M, Pollard, C, Radford, J, Roome, N, Sager, P, Singh, S, Suter, T, Suter, W, Trafford, A, Volders, P, Wallis, R, Weaver, R, York, M, Valentin, J

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. od Ogbe, A, Kronsteiner, B, Skelly, DT, Pace, M, Brown, A, Adland, E, Adair, K, Akhter, HD, Ali, M, Ali, S-E, Angyal, A, Ansari, MA, Arancibia-Cárcamo, CV, Brown, H, Chinnakannan, S, Conlon, C, de Lara, C, de Silva, T, Dold, C, Dong, T, Donnison, T, Eyre, D, Flaxman, A, Fletcher, H, Gardner, J, Grist, JT, Hackstein, C-P, Jaruthamsophon, K, Jeffery, K, Lambe, T, Lee, L, Li, W, Lim, N, Matthews, PC, Mentzer, AJ, Moore, SC, Naisbitt, DJ, Ogese, M, Ogg, G, Openshaw, P, Pirmohamed, M, Pollard, AJ, Ramamurthy, N, Rongkard, P, Rowland-Jones, S, Sampson, O, Screaton, G, Sette, A, Stafford, L, Thompson, C, Klenerman, P, Frater, J, Dunachie, S